The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins
- PMID: 8224164
- DOI: 10.1016/0014-5793(93)80367-4
The gag precursor contains a specific HIV-1 protease cleavage site between the NC (P7) and P1 proteins
Abstract
The predicted protease cleavage site (p7/p1; [J. Virol. 66 (1992) 1856-1865]) within the nucleocapsid precursor protein (p15) of human immunodeficiency virus, type 1, was confirmed using an in vitro assay employing recombinant HIV-1 protease and a chemically synthesized 72 amino acid polypeptide containing the p7 and p1 protein domains of the native gag polyprotein. The cleavage occurred between amino acid 55 (N) and amino acid 56 (F) of the polypeptide, as determined by N-terminal sequencing. The hydrolysis was optimal at pH 6.0 and at high salt concentration. The kinetic parameters Km, kcat and kcat/Km were 99 microM (+/- 8), 0.152 s-1 (+/- 0.002) and 1.56 mM-1.s-1 (+/- 0.11), respectively. Reconstituted as well as denatured polypeptides were cleaved at approximately the same rate, demonstrating that the conformation of the p7 protein, as a result of the Zn(2+)-binding, had no significant effect on the rate of hydrolysis of the p7/p1 cleavage.
Similar articles
-
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.Virology. 2002 Jan 5;292(1):137-49. doi: 10.1006/viro.2001.1184. Virology. 2002. PMID: 11878916
-
Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266. Virology. 1996. PMID: 8638406
-
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.J Virol. 1997 Sep;71(9):6662-70. doi: 10.1128/JVI.71.9.6662-6670.1997. J Virol. 1997. PMID: 9261388 Free PMC article.
-
Subsite preferences of retroviral proteinases.Methods Enzymol. 1994;241:254-78. doi: 10.1016/0076-6879(94)41068-2. Methods Enzymol. 1994. PMID: 7854181 Review. No abstract available.
-
Activation mechanism of pepsinogen as compared to the processing of HIV protease gag-pol precursor protein.Adv Exp Med Biol. 1998;436:245-52. doi: 10.1007/978-1-4615-5373-1_34. Adv Exp Med Biol. 1998. PMID: 9561226 Review. No abstract available.
Cited by
-
Effect of mutation on the stabilization energy of HIV-1 zinc fingers: a hybrid local self-consistent field/molecular mechanics investigation.J Biol Inorg Chem. 2017 Jan;22(1):109-119. doi: 10.1007/s00775-016-1411-6. Epub 2016 Nov 15. J Biol Inorg Chem. 2017. PMID: 27848035
-
Processing sites in the human immunodeficiency virus type 1 (HIV-1) Gag-Pro-Pol precursor are cleaved by the viral protease at different rates.Retrovirology. 2005 Nov 1;2:66. doi: 10.1186/1742-4690-2-66. Retrovirology. 2005. PMID: 16262906 Free PMC article.
-
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.J Virol. 1997 Feb;71(2):1089-96. doi: 10.1128/JVI.71.2.1089-1096.1997. J Virol. 1997. PMID: 8995629 Free PMC article.
-
Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability.J Mol Model. 2011 Feb;17(2):391-9. doi: 10.1007/s00894-010-0739-z. Epub 2010 May 18. J Mol Model. 2011. PMID: 20480379
-
Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues.EMBO J. 1994 Apr 1;13(7):1525-33. doi: 10.1002/j.1460-2075.1994.tb06414.x. EMBO J. 1994. PMID: 8156990 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
